Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China
Our study revealed that IMID biosimilars in China provide clinical benefits comparable to their reference biologics evidenced by high-quality RCTs and cohort studies with offer significant cost savings in China. Encouraging China's national volume-based procurement and multi-stakeholder collaboration may help accelerate the substitution of IMIDs biosimilars.
Authors
- Xin Du (ORCID: https://orcid.org/0000-0003-1494-4910)
- Xingxian Luo
- Wencheng Zhou (ORCID: https://orcid.org/0000-0001-6160-4551)
- Ziling Su
- Qixiang Guo (ORCID: https://orcid.org/0000-0002-0794-5918)
- Jiarun Li (ORCID: https://orcid.org/0000-0002-4770-4887)
- Yi Zhang (ORCID: https://orcid.org/0000-0002-1113-8465)
- Yang Yue (ORCID: https://orcid.org/0000-0002-6102-9240)
- Zhongjian Wang (ORCID: https://orcid.org/0000-0002-4946-969X)
- Xiaomeng Jiang (ORCID: https://orcid.org/0009-0001-3740-3351)
Institutions
- Sun Yat-sen University (CN)
- Massachusetts College of Pharmacy and Health Sciences (US)
- Peking University (CN)
- National Medical Products Administration (CN)
- Peking University People's Hospital (CN)
- Vanke (China) (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2024-12-04
- DOI
- https://doi.org/10.3389/fpubh.2024.1476213
- Citations
- 11
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 2.65
Funders
- National Natural Science Foundation of China
- Tsinghua University